MannKind Corporation
ロング
更新済

MNKD 10x Potential, High R/R

625
Rapidly Hiring. They have a proprietary drug delivery platform known as the Technosphere. They deliver drugs through the lungs instead of injection or pills.

Afrezza their FDA approved drug is finally starting to generate sales after being fda approved years ago.

They are also working on several other products for 2020.

Huge accumulation range and due to very aggressive short sellers flooding the market with over 40 million additional shares over the years.

All of these short sales will eventually be pressured to rebuy rapidly driving up price. There are also warrants that were delayed and expire in July.

With the healthcare sector and biotech improving at a rapid pace, an effective product, all the catalysts are there.

ノート
Target is still $8
ノート
$10
ノート
Update to $20

免責事項

これらの情報および投稿は、TradingViewが提供または承認する金融、投資、取引、またはその他の種類の助言もしくは推奨であることを意図したものではなく、またこれらに該当するものでもありません。詳細は利用規約をご覧ください。